Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study

Abstract

We conducted a randomized, controlled study to assess the need for hydroxychloroquine (HCQ) during lupus pregnancy and to assess safety. Twenty consecutive pregnant patients with similar characteristics were enrolled. The HCQ group included eight patients with systemic lupus erythematosus (SLE) and two with discoid lupus erythematosus (DLE). The placebo (PL) group included nine patients with SLE and one with DLE. The HCQ group had no flare-ups. SLEPDAI scores were similar at study entry, and at conclusion the placebo group had significantly higher scores. One patient had improvement of skin lesions and another of arthritis, allowing a decrease of prednisone dose. There were no retinal effects. Three patients in the PL group flared up, two with skin rashes, one also with arthritis and uveitis, and one (previously in remission on HCQ) with hemolytic anemia, polyserositis and anti-dsDNA antibody. Toxemia was diagnosed in only three patients in the PL group (one fetal death). Comparing prednisone dosage change, we noted a decrease in the HCQ and an increase in the PL group. Delivery age and Apgar scores were higher in the HCQ group. Neonatal examination did not reveal congenital abnormalities, nor did a neuroophthalmological and auditory evaluation at 1.5–3 y of age. In spite of the small number of patients studied, we noted beneficial effects of HCQ during lupus pregnancy, as measured by SLEPDAI and decrease in prednisone dose with no detriment to patients' health.

Keywords

lupus pregnancy antimalarials hydroxychloroquine

Get full access to this article

View all access options for this article.

References

Ruiz-Irastorza G , Lima F , Alves J et al. Increased rate of lupus flare during pregnancy and puerperium: a prospective study of 78 pregnancies . Br J Rheumatol 1996; 35: 133–138 .

Petri M , Howard D , Repke J . Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience . Arthritis Rheum 1991; 34: 1538–1545 .

Rynes RI . Antimalarial drugs in the treatment of rheumatological diseases . Br J Rheumatol 1997; 36: 799–805 .

Fox R . Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development . Lupus 1996; 5(Suppl): S4-S10 .

Lockshin MD . Therapy for systemic lupus erythematosus . New Engl J Med 1991; 324: 189–191 .

Gladman DD , Urowitz MB , Senecal JL et al. Aspects of use of antimalarials in systemic lupus erythematosus . J Rheumatol 1998; 25: 983–985 .

The Canadian Hydroxychloroquine Study Group: a randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus . New Engl J Med 1991; 324: 150–154 .

Tsakonas E , Joseph L , Esdaile JM et al. A long-term study of hydroxychloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group . Lupus 1998; 7: 80–85 .

Petri M . Hydroxychloroquine use in Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis . Lupus 1996; 5(Suppl): S16-S22 .

10.

Wallace DJ . Antimalarial agents and lupus . Rheum Dis Clin N Am 1994; 20: 243–263 .

11.

Kallen B . The teratogenicity of antirheumatic drugs: what is the evidence? Scand J Rheumatol 1998; 27: 119–124 .

12.

Matz GJ , Naunton RF . Ototoxicity of chloroquine . Arch Otolaryngol 1968; 88: 370–372 .

13.

Ullberg S , Lindquist NG , Sjöstrand SE . Accumulation of chorioretinotoxic drugs in the foetal eye . Nature 1970; 19: 1257–1258 .

14.

Buchanan NM , Khamashta MA , Morton KE , Kerslake S , Baguley EA , Hughes GRV . A study of 100 high-risk pregnancies . Am J Reprod Immunol 1992; 28: 192–194 .

15.

Parke AL , West B . Hydroxychloroquine in pregnant patients with systemic lupus erythematosus . J Rheumatol 1996; 23: 1715–1718 .

16.

Buchanan NM , Toubi E , Khamashta MA , Lima F , Kerslake S , Hughes GRV . Hydroxychloroquine and lupus pregnancy: review of a series of 36 cases . Ann Rheum Dis 1996; 55: 486–488 .

17.

Parke AL , Rothfield NF . Antimalarial drugs in pregnancy: the North American experience . Lupus 1996; 5: S67–S69 .

18.

Levy M , Buskila D , Gladman DD , Urowitz MB , Koren G . Pregnancy outcome following first trimester exposure to chloroquine . Am J Perinatol 1991; 8: 174–178 .

19.

Buyon JP , Kallunian KC , Ramsey-Goldman R et al. Assessing disease activity in SLE patients during pregnancy . Lupus 1999; 8: 677–684 .

20.

Hardman JG , Limbird JE , Molinoff PB , Ruddon RW , Gilman AG . Antimalarials. In: Goodman and Gilman's: the Pharmacological Basis of Therapeutics. McGraw-Hill, Teton Data Systems: Jackson Hole, WY , 1996.

21.

Petri M . Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective . Scand J Rheumatol 1996; 25: 191–193 .

22.

Johnson R , Charnley J . Hydroxychloroquine on prophylaxis of pulmonary embolism following hip artrhroplasty . Clin Orthoped 1979; 144: 174–177 .

23.

Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum 1982; 25: 1272–1277 .

24.

Easterbrook M , Bernstein H . Ophthalmological monitoring of patients taking antimalarials: preferred practice patterns . J Rheumatol 1997; 24: 1390–1392 .

25.

Silman A , Shipley M . Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data . Br J Rheumatol 1997; 36: 599–601 .